Access to cancer drugs in Medicare Part D: Formulary placement and beneficiary cost sharing in 2006

被引：15

作者：

Bowman, Jennifer ^{[1
]}

Rousseau, Amy ^{[1
]}

Silk, David ^{[1
]}

Harrison, Catherine ^{[1
]}

机构：

[1] Avalere Hlth LLC, Washington, DC USA

来源：

HEALTH AFFAIRS | 2006年 / 25卷 / 05期

关键词：

D O I：

10.1377/hlthaff.25.5.1240

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

The Medicare Part D benefit expands the universe of cancer drugs and biologics that Medicare may cover. Individual Part D plans have discretion to determine their formularies and cost sharing for drugs within federal guidelines. This paper analyzes differences in coverage and cost sharing for cancer drugs among these plans. We find that many cancer drugs, including brand-name products, are covered by almost all plans, although prior authorization might limit access to some. In addition, many plans charge a relatively low copayment for most cancer drugs. These findings suggest that Part D could greatly expand beneficiaries' access to cancer treatments.

引用

页码：1240 / 1248

页数：9